| 17.95 -0.37 (-2.02%) | 10-24 14:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.71 | 1-year : | 26.53 |
| Resists | First : | 19.45 | Second : | 22.71 |
| Pivot price | 17.5 |
|||
| Supports | First : | 15.07 | Second : | 12.36 |
| MAs | MA(5) : | 17.75 |
MA(20) : | 17.19 |
| MA(100) : | 12.26 |
MA(250) : | 12.69  |
|
| MACD | MACD : | 1 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 56.5 |
D(3) : | 52.2 |
| RSI | RSI(14): 60.9 |
|||
| 52-week | High : | 30 | Low : | 0.56 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LYEL ] has closed below upper band by 30.2%. Bollinger Bands are 28.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.35 - 18.45 | 18.45 - 18.54 |
| Low: | 16.77 - 16.9 | 16.9 - 17.02 |
| Close: | 18.12 - 18.32 | 18.32 - 18.5 |
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Fri, 26 Sep 2025
LUCID CAPITAL MARKETS Initiates Coverage of Lyell Immunopharma (LYEL) with Buy Recommendation - Nasdaq
Tue, 02 Sep 2025
Clinical-Stage CAR T-Cell Therapy Developer Lyell Immunopharma Announces Key September Investor Presentations - Stock Titan
Tue, 02 Sep 2025
Lyell Immunopharma Announces Participation in September Investor Conferences - Yahoo Finance
Tue, 12 Aug 2025
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 - GlobeNewswire
Fri, 25 Jul 2025
Lyell Immunopharma, Inc. Secures $100 Million in Private Placement to Advance CAR T-Cell Therapy Trials - Quiver Quantitative
Fri, 25 Jul 2025
Lyell Immunopharma secures up to $100 million in private placement - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 1.205e+007 (%) |
| Held by Institutions | 20.5 (%) |
| Shares Short | 146 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.9487e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -541 % |
| Return on Assets (ttm) | 212.5 % |
| Return on Equity (ttm) | -25.4 % |
| Qtrly Rev. Growth | 60000 % |
| Gross Profit (p.s.) | 0.33 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -0.76 |
| Qtrly Earnings Growth | -24.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -171 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 93.46 |
| Price to Cash Flow | -0.08 |
| Dividend | 0 |
| Forward Dividend | 233070 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|